Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference activity for the first quarter of 2019.
Cambridge, UK, 28 January 2019 –Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference activity for the first quarter of 2019.
- Microbiome Drug Development Summit, 28-30 January 2019, Paris, France
The conference is designed to tackle the greatest scientific, regulatory, clinical, manufacturing and commercialisation challenges across the entire drug development value chain. Microbiotica is also a sponsor of this key event.
‘Precision Metagenomics Microbiome Analysis in Personalised Medicine’ – talk by Dr Trevor Lawley,
29 January, 11.30 – 11.50
‘New Perspectives on Pharma & Biotech Partnerships in the Microbiome’ – panel featuring Dr Mike Romanos,
29 January, 16.20 – 17.00
- What’s New In Microbiome Research, 12 February 2019, Babraham Research Campus, UK
This event will provide a summary of the latest trends, research and industry thinking in the microbiome field, and will feature a presentation from Mike Romanos and other leading experts in the field.
‘Identifying gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers’ - presentation by Dr Mike Romanos, evening event 17.30 – 21.30
- ENDS -
For more information please contact:
Microbiotica
Rowena Gardner
rgardner@microbiotica.com
+44 1223 786063 / +44 7801 480569
Instinctif Partners (for media enquiries)
Sue Charles/Deborah Bell
microbiotica@instinctif.com
+44 20 7866 7860
Notes to editors
About Microbiotica
Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute. The Company was founded by Dr Mike Romanos, Dr Trevor Lawley and Professor Gordon Dougan, FRS. Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute. It has a strategic collaboration with Genentech, a member of the Roche Group, in the field of inflammatory bowel disease (IBD) as well as with University of Adelaide to develop a defined product for ulcerative colitis.
Microbiotica has attracted £12m in equity investment from Cambridge Innovation Capital, IP Group plc and Seventure Partners.
For more information, please visit www.microbiotica.com, LinkedIn and Twitter.
About Microbiotica’s platform
The Microbiotica platform comprises the world’s leading microbiome Culture Collection and linked Reference Genome Database that enable unprecedented precision of gut bacterial identification The Company is adding to this at a very rapid rate through its industrial culturing and sequencing pipeline, providing the best available representation of clinical trial samples for strain-level identification of bacteria. The complex datasets that arise from such studies are analysed using AI techniques to discern microbiome signatures linked to phenotype. The availability of the physical Culture Collection enables biological evaluation of bacteria in proprietary translational models including humanised microbiome mouse models.
About the Microbiome
Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.
